Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in the Netherlands during 2000 to 2004

Value in Health

Volumn 12, Issue 6, 2009, Pages 909-914

  Van Der Linden, Michiel W ^a   Plat, Arian W ^a   Erkens, Joelle A ^a   Emneus, Martha ^b   Herings, Ron M C ^a,c  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b NOVO NORDISK A S   (Denmark)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Diabetes mellitus; Diabetes related complications; Direct costs; Pharmacy; Prevention and control

Indexed keywords

ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; INSULIN; ORAL ANTIDIABETIC AGENT;

ADOLESCENT; ADULT; AGED; AMPUTATION; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; INFANT, NEWBORN; INSULIN; MALE; MEDICAL RECORD LINKAGE; MIDDLE AGED; NETHERLANDS; YOUNG ADULT;

EID: 67651236019     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00506.x     Document Type: Article

References (23)

1. WHO. Diabetes mellitus. 2006. Available from: http://www.who.int/ mediacentre/factsheets/fs312/en/index.html [Accessed September 9, 2008].
2. Van Oers JAM. Health on course? The 2002 Dutch public health status and forecasts report. Report No.: 270551001. Bilthoven, The Netherlands : National Institute for Public Health and the Environment, 2002.
3. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the study of diabetes (EASD). Eur Heart J 2007 28 : 88 136.
4. Burgers JS, Bailey JV, Klazinga NS, et al. Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. Diabetes Care 2002 25 : 1933 9.
5. Rutten GEHM, De Grauw WJC, Nijpels G, et al. NHG-standaard diabetes mellitus type 2 (tweede herziening) (NHG practice guideline diabetes mellitus type 2 (second revision). Huisarts Wet 2006 49 : 137 52.
6. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007 30 : 162 72.
7. Brandle M, Herman WH. The CORE Diabetes Model. Curr Med Res Opin 2004 20 (Suppl. 1 S1 3.
8. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004 20 (Suppl. 1 S5 26.
9. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004 20 (Suppl. 1 S27 40.
10. Erkens JA, Klungel OH, Stolk RP, et al. Cardiovascular drug use and hospitalizations attributable to type 2 diabetes. Diabetes Care 2001 24 : 1428 32.
11. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992 46 : 136 40.
12. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999 159 : 1873 80.
13. Goettsch WG, van den Boom G, Breekveldt-Postma NS, et al. Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study. Pharmacoepidemiol Drug Saf 2004 13 : 803 10.
14. Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001 19 : 655 65.
15. Wiedijk IS, Spierings P. Technische brochure: Opbouw en Organisatie van het CBV-bestand [Dutch]. Leiden, The Netherlands : Stichting CBV, 1999.
16. Statistics-Netherlands-(CBS). Statistisch Jaarboek. Voorburg/Heerlen : Statistics Netherlands (CBS), 2004.
17. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008 31 : 596 615.
18. Martin S, Schramm W, Schneider B, et al. Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4). Exp Clin Endocrinol Diabetes 2007 115 : 495 501.
19. Bruno G, Karaghiosoff L, Merletti F, et al. The impact of diabetes on prescription drug costs: the population-based Turin study. Diabetologia 2008 51 : 795 801.
20. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003 26 : 917 32.
21. Eppens MC, Craig ME, Cusumano J, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care 2006 29 : 1300 6.
22. Nield L, Summerbell CD, Hooper L, et al. Dietary advice for the prevention of type 2 diabetes mellitus in adults. Cochrane Database Syst Rev 2008 CD005102.
23. Spijkerman AM, Dekker JM, Nijpels G, et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. Diabetes Care 2003 26 : 2604 8.